Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
28 May 2021 07:00 BST Tagrisso approved in the EU for the adjuvant treatmentof patients with early-stage EGFR-mutated lung cancer Approval based on unprecedented results from the ADAURA Phase III trialwhere Tagrisso reduced the risk of disease recurrence or death by 80% AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent. Tagrisso